WallStreetZenWallStreetZen

NASDAQ: MLTX
Moonlake Immunotherapeutics Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Moonlake Immunotherapeutics earnings were -$147.8M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest MLTX earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$40.6M, down 12.6% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, MLTX reported annual earnings of -$121.2M, with 175.1% growth.

MLTX earnings history

Current Revenue
$0.0
Current Earnings
-$147.8M
Current Profit Margin
0%

MLTX Return on Equity

Current Company
-31.7%
Current Industry
-60.2%
Current Market
31.5%
MLTX's Return on Equity (-31.7%)... subscribe to Premium to read more.
High Return on Equity Performance

MLTX undefined

Current Company
-28.8%
Current Industry
-2.5%
MLTX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when MLTX announces earnings.

MLTX undefined

Current Company
-30.26%
Current Industry
5.8%
MLTX's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

MLTX vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
MLTX-$145.71M-$147.83MN/A-$2.30
CPRX$296.55M$197.35M+31.48%$1.65
VKTX-$127.85M-$128.24MN/A-$1.15
AAPG-$32.47M-$55.46MN/A-$0.73
IBRX-$240.81M-$409.10MN/A-$0.54
View Top Biotech Stocks

Moonlake Immunotherapeutics Earnings Reports & History FAQ

What were Moonlake Immunotherapeutics's earnings last quarter?

On MLTX's earnings call on Invalid Date, Moonlake Immunotherapeutics (NASDAQ: MLTX) reported Q1 2025 earnings per share (EPS) of -$0.63, up 186.36% year over year. Total MLTX earnings for the quarter were -$40.56 million. In the same quarter last year, Moonlake Immunotherapeutics's earnings per share (EPS) was -$0.22.

If you're new to stock investing, here's how to buy Moonlake Immunotherapeutics stock.

Is Moonlake Immunotherapeutics profitable or losing money?

As of the last Moonlake Immunotherapeutics earnings report, Moonlake Immunotherapeutics is currently losing money. Moonlake Immunotherapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$147.83 million, a 222.52% increase year over year.

What was MLTX's earnings growth in the past year?

As of Moonlake Immunotherapeutics's earnings date in Invalid Date, Moonlake Immunotherapeutics's earnings has grown year over year. MLTX earnings in the past year totalled -$147.83 million.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.